Shares of Sun Pharmaceutical Industries Ltd. surged by almost 3% to touch a day’s high of Rs 1,712.40 on 26 July after announcing USFDA approval for Deuruxolitinib, a new drug for treating Alopecia Areata.

The drug will be sold under the brand name LEQSELVI, and 8 mg tablets will be available for the treatment. Two pivotal Phase 3 studies involving approximately 1,220 patients provided the evidence behind this clearance. The USFDA approved the filing acceptance of the NDA for deuruxolitinib.

According to Sun Pharma North America Business CEO, Mr. Abhay Gandhi, LEQSELVI will provide a new and viable treatment option for the management of patients with severe alopecia areata. The dermatology business of Sun Pharma is very pleased to have this new drug added to its portfolio.

During the initial phase, the average patient had only 13% scalp hair coverage, and at the 24-week mark, one-third of patients had 80% scalp hair coverage.

Alopecia areata is a common autoimmune disease causing hair loss. The disease arises from the immune system attacking hair follicles. It can lead to sudden hair loss on the scalp, face, and sometimes other body areas.

In the foreseeable three to four years, this medicine can generate an expected revenue of $200 million. It will be a new addition to Sun Pharma’s specialty portfolio.

At 12:16 PM, the shares of Sun Pharma were trading 1.52% higher at Rs 1,691.05 on BSE.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!